Kengo Watanabe

Years Active: 2019-2019
Publications (10 Years): 1

Daiichi-Sankyo (Japan)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Daiichi-Sankyo (Japan) Apr 01 1998

Japan

Senior Director :: Drug Metabolism & Pharmacokinetics Research Laboratories

Publications

Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima, Yuki Shimizu, Yosuke Seto, Tomoko Oh-Hara, Sumie Koike, Naoki Nakao, Hiroyuki Hanzawa, Kengo Watanabe, Satoshi Yoda, Noriko Yanagitani, Aaron N Hata, Alice T Shaw, Makoto Nishio, Naoya Fujita, Takeshi Isoyama
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nature communications 10 (1) (2019)

Kengo Watanabe.css-eqlu8i{font-size:small;padding-left:4px;}